ACUMEN PHARMACEUTICALS INC (ABOS) Stock Earnings & Estimates
NASDAQ:ABOS - US00509G2093 - Common Stock
1.36 USD
+0.05 (+3.82%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.7M | 1.44M -15.29% | -100.00% | 47.234M | 112.82M 138.85% | 231.57M 105.26% | |||||||||
| EBITDA YoY % growth | N/A | N/A | -16.395M | -41.206M -130.90% | -58.074M -34.52% | -108.059M -87.16% | -147.051M -29.19% | 28.185B 19,266.86% | 45.041B 59.80% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -7.81M | -7.91M -1.28% | -37.949M -147.53% | -42.101M -131.05% | -59.947M -34.84% | -105.903M -86.89% | -139.081M -22.00% | -123.353M 11.31% | -130.765M -6.01% | -70.44M 46.13% | -81.339M -15.47% | -55.46M 31.82% | -8.057M 85.47% | 88.25M 1,195.32% | |
| Operating Margin | -459.41% | -549.31% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -117.42% | -7.14% | 38.11% | |
| EPS YoY % growth | N/A | N/A | -3.78 | -1.00 71.98% | -1.09 -1.89% | -1.61 -58.33% | -2.34 -36.98% | -1.68 28.16% | -1.42 15.38% | -2.20 -54.73% | -2.07 6.02% | -0.36 82.76% | 0.64 280.00% | 2.13 231.75% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.58 -15.87% | -0.52 15.69% | -0.47 2.25% | -0.43 37.00% | -0.44 24.30% | -0.41 21.95% |
| Revenue Q2Q % growth | ||||||
| EBITDA Q2Q % growth | -31.644M 1.51% | -33.669M 14.59% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -33.491M -3.80% | -34.105M 13.87% | -28.182M 7.21% | -22.488M 46.14% | -23.459M 29.95% | -24.476M 28.23% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.68 -100.00% | -0.55 | -0.13 | -23.92% |
| Q1 2025 Q2Q % growth | -0.48 -92.00% | -0.68 | 0.20 | 29.06% |
| Q4 2024 Q2Q % growth | -0.62 -121.43% | -0.49 | -0.13 | -26.63% |
| Q3 2024 Q2Q % growth | -0.50 -108.33% | -0.37 | -0.13 | -34.30% |
| Q2 2024 Q2Q % growth | -0.34 -21.43% | -0.29 | -0.05 | -19.05% |
| Q1 2024 Q2Q % growth | -0.25 10.71% | -0.27 | 0.02 | 5.73% |
| Q4 2023 Q2Q % growth | -0.28 12.50% | -0.27 | -0.01 | -5.58% |
| Q3 2023 Q2Q % growth | -0.24 7.69% | -0.27 | 0.03 | 11.54% |
| Q2 2023 Q2Q % growth | -0.28 -12.00% | -0.35 | 0.07 | 20.66% |
| Q1 2023 Q2Q % growth | -0.28 -21.74% | -0.35 | 0.07 | 20.66% |
| Q4 2022 Q2Q % growth | -0.32 23.08% | -0.26 | -0.06 | -22.84% |
| Q3 2022 Q2Q % growth | -0.26 -160.00% | -0.23 | -0.03 | -10.92% |
| Q2 2022 Q2Q % growth | -0.25 96.84% | -0.25 | 0.00 | -0.04% |
| Q1 2022 Q2Q % growth | -0.23 | -0.17 | -0.06 | -35.84% |
| Q4 2021 Q2Q % growth | -0.42 | -0.14 | -0.27 | -187.21% |
| Q3 2021 Q2Q % growth | -0.10 | -0.17 | 0.07 | 42.44% |
| Q2 2021 Q2Q % growth | -7.91 | -4.65 | -3.26 | -70.21% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2021 Q2Q % growth | -100.00% | % | ||
| Q3 2021 Q2Q % growth | -100.00% | % | ||
| Q2 2021 Q2Q % growth | -100.00% | % | ||
| Q1 2021 Q2Q % growth | -100.00% | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -9.76% | -10.29% | -7.06% | -7.9% |
| Revenue | N/A | N/A | N/A | N/A |